4.42 USD
▲+0.02+1.38%
盘后 4.31 -1.15%
2026-08-03
市值
$873.12M
市盈率
5.29
EPS
0.83
股息率
—
52 周区间
3.26 – 5.38
成交量
958.66K
Beta
0.62
目标价
5.18
52W 低 3.2652W 高 5.38
价格走势
公司简介
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh...